Edgewise Therapeutics에 대한 매도 수량은 투자자에게 Edgewise Therapeutics의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Edgewise Therapeutics (NASDAQ:EWTX) 주식, 공매도 수량 보고

Edgewise Therapeutics

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

Mid Cap

News

Movers

Trading Ideas

ASND

BLCO

EWTX

NUVL

POWL

지난주 연방준비제도(연준)가 금리를 50bp(베이시스 포인트) 인하하기로 결정하면서 기술, 건설, 산업, 기계 그리고 금융 부문 전반에 걸쳐 주가가 상승했다. 지난주 가장 좋은 실적을 보인 중형주 7종목은 다음과 같다. 여러분의 포트폴리오에 포함되어 있나요?

바우쉬 헬스와 엣지와이즈는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (9월 15일-9월 21일)

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics Inc

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf</a>

Markets

FOUR

Shift4 Payments Will Replace R1 RCM In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Wednesday, November 20

China Green Agriculture, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGA#NYSE">CGA</a>) has changed its name to Enlightify Inc., effective November 25, 2024. Its ticker symbol will change to ENFY effective November 25, 2024, and it is expected to begin trading under that symbol on November 26, 2024. The Company mainly produces and distributes humic acid-based compound fertilizers, other varieties of compound fertilizers and agricultural products through its subsidiaries in China.

China Green Agriculture Changes Name to Enlightify Inc.; Its Ticker Symbol Will Change To 'ENFY' Effective November 25, 2024, And It Is Expected To Begin Trading Under That Symbol On November 26, 2024

Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) reported quarterly losses of $(0.31) per share. This is a 63.1 percent increase over losses of $(0.84) per share from the same period last year.

Earnings

ACOG

Alpha Cognition Q2 EPS $(0.31) Up From $(0.84) YoY

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

Price Target

Analyst Ratings

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

Luna Innovations Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNA#NASDAQ">LUNA</a>) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that it has received a written notice (the "Notice") on November 14, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the quarter ended September 30, 2024 (the "Q3 2024 Form 10-Q") and because the Company remains delinquent in filing its Form 10-Qs for the quarters ended March 31, 2024 (the "Q1 2024 Form 10-Q") and June 30, 2024 (the "Q2 2024 Form 10-Q") and its Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K", and collectively with the Q1 2024 10-Q, Q2 2024 10-Q and Q3 2024 10-Q, the "Delinquent Filings"), it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). As previously announced, the Company received earlier notices of non-compliance with respect to the Rule on August 20, 2024, May 17, 2024 and April 2, 2024 because it had not yet filed its Q2 2024 Form 10-Q, Q1 2024 Form 10-Q and 2023 Form 10-K, respectively.
This Notice has no immediate effect on the listing of the Company's shares on Nasdaq. However, if the Company fails to timely regain compliance with the Rule, the Company's common stock will be subject to delisting from Nasdaq.
As previously disclosed on October 7, 2024, the Company intended to appeal a determination by the Nasdaq Listing Qualifications Department to delist the Company's securities due to the Company's Delinquent Filings. On October 8, 2024, the Company timely requested a hearing before the Nasdaq Hearings Panel (the "Panel") and requested that the automatic stay of suspension be extended through the completion of the hearings process and the expiration of any additional extension period granted by the Panel following the hearing. The hearing is scheduled for November 26, 2024 and the request for the automatic stay of suspension was granted.
The Company is working diligently to complete its Delinquent Filings and will provide an update once more information is available.

LUNA

Luna Innovations Receives Additional Notice From Nasdaq Regarding Late Filing Of Quarterly Report On Form 10-Q; Hearing Is Scheduled For November 26, 2024 And The Request For The Automatic Stay Of Suspension Was Granted

Barrington Research analyst Kevin Steinke maintains HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) with a Outperform and raises the price target from $17 to $18.

Barrington Research Maintains Outperform on HireQuest, Raises Price Target to $18

Barrington Research analyst Vincent Colicchio maintains Alithya Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ALYA#TSX">ALYA</a>) with a Outperform and maintains C$3.5 price target.

TSX:ALYA

Barrington Research Maintains Outperform on Alithya Group, Maintains C$3.5 Price Target

Lifeway Foods, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWAY#NASDAQ">LWAY</a>) ("Lifeway" or the "Company"), a leading U.S. supplier of kefir and fermented probiotic products to support the microbiome, confirmed that it has received a revised, unsolicited, non-binding proposal from Danone North America PBC ("Danone") to acquire all outstanding shares of common stock of Lifeway it does not already own for $27.00 per share in cash. According to the Schedule 13D amendment filed today with the U.S. Securities and Exchange Commission disclosing the revised proposal, Danone beneficially owns approximately 23.3% of Lifeway's outstanding common stock.
On November 5, 2024, Lifeway announced that its Board of Directors (the "Board") had rejected Danone's initial unsolicited, non-binding proposal to acquire all the shares of Lifeway that it does not already own for $25.00 per share because the Board determined that the initial proposal substantially undervalued Lifeway and was not in the best interests of the Company and its shareholders and other stakeholders.
Consistent with its fiduciary duties, Lifeway's board of directors, in consultation with its independent outside advisors, will carefully review and evaluate the revised proposal to determine the course of action that it believes is in the best interests of the Company and its shareholders and other stakeholders.
The Company does not undertake any obligation to provide any updates with respect to this or any other proposal or transaction, except as required under applicable law.
Lifeway shareholders do not need to take any action at this time.
Evercore is serving as a financial advisor to Lifeway and Sidley Austin LLP is serving as legal counsel to Lifeway.

LWAY

Lifeway Foods Confirms Receipt Of Revised, Unsolicited, Non-Binding Proposal From Danone  To Acquire All Outstanding Shares Of Common Stock Of Lifeway It Does Not Already Own For $27.00 Per Share In Cash

Generation Income (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIPR#NASDAQ">GIPR</a>) reported quarterly losses of $(0.03) per share. This is unchanged from the same period last year. The company reported quarterly sales of $2.40 million which beat the analyst consensus estimate of $2.26 million by 6.21 percent. This is a 30.17 percent increase over sales of $1.84 million the same period last year.

Earnings Beats

GIPR

Generation Income Q3 FFO $(0.03), Same YoY, Sales $2.40M Beat $2.26M Estimate

Shareholders Approve Waiver Of 19.99% Limit To Enable Additional Stock Issuance

Stock Split

LUXH

LuxUrban Hotels Announces 1-For-70 Reverse Stock Split Effective Nov. 20 To Strengthen Nasdaq Compliance

COIN RISES OVER 9% AT THE HIGH OF THE DAY
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="646" height="677" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/15210221/Screen-Shot-2024-11-15-at-4.06.36-PM.png" alt="" class="wp-image-3372" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/15210221/Screen-Shot-2024-11-15-at-4.06.36-PM.png 646w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/15210221/Screen-Shot-2024-11-15-at-4.06.36-PM-286x300.png 286w" sizes="(max-width: 646px) 100vw, 646px" /></figure>
Today, Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:08 AM on November 15th, a significant trading signal occurred for Coinbase Global, Inc.as it demonstrated a Power Inflow at a price of $280.69. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Coinbase&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Coinbase&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for COIN, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data are brought to you by Benzinga APIs</a> and include firms, like <a href="https://finitusa.com/en/">Finit USA</a>, responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $280.69. The returns on the high price ($306.17) and close price ($305.82)&nbsp;after the power inflow were&nbsp;9.0% and 8.7%&nbsp;respectively. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case, the high of the day and close were very close but that is not always the case
Past Performance is Not Indicative of Future Results

Signals

COIN

Tradepulse Power Inflow Alert: Coinbase Global Inc. Receives Alert And Climbs Over 25 Points

Patrick Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PATK#NASDAQ">PATK</a>) ("Patrick" or the "Company") today announced that on November 14, 2024, its Board of Directors (the "Board") approved an increase in the amount of its quarterly cash dividend on its common stock to $0.60 per share from $0.55 per share. The dividend is payable on December 9, 2024 to shareholders of record at the close of business on November 25, 2024. Additionally, the Board authorized an increase in the amount of the Company's common stock that may be acquired over the next 24 months under the current stock repurchase program to $200.0 million, including the $72.9 million remaining under the previous authorization.

Dividends

Buybacks

PATK

Patrick Industries, Inc. Announces Increase To Regular Quarterly Cash Dividend From $0.55 To $0.60 Per Share, And Increased Share Repurchase Authorization To $200M, Including The $72.9M Remaining Under The Previous Authorization

NVNI

Nvni Group Limited Receives Nasdaq Delisting Notice For Non-Compliance With Filing Requirements; Appeals To Nasdaq Hearings Panel For Extended Stay To Maintain Listing

The yield on the 10-year Treasury bond is not too far from the critical 5% mark, and for investors, this could be the financial equivalent of <a href="https://www.benzinga.com/topic/interest-rates">a seismic portfolio shift.</a>
Historically, when bond yields rise this high, they don't just invite competition with stocks: They start stealing the show.
In a note shared with clients on Friday, Bank of America analyst Savita Subramanian indicated that a 5% yield is the level at which bonds start to be more attractive than stocks.
Here's the logic: stocks carry risk, volatility, and higher expected returns. Bonds, especially Treasuries, the opposite. 
If both assets, for some reason, offer a similar return, why bother with the headaches of equities?
The logic is tied to the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41950023/us-stock-markets-equity-risk-premium-disappears-should-you-sell-now">equity risk premium (ERP)</a> — the extra return investors demand for holding riskier stocks instead of safer bonds. 
Suppose a 10-year Treasury bond yields a 5% return with virtually no risk. In that case, it becomes harder to justify holding volatile equities unless they can deliver returns well above that level.
Also Read: <a href="https://www.benzinga.com/24/11/42015996/tesla-to-partner-with-lyft-uber-analyst-says-rising-conviction-for-partnership-in-future">Tesla To Partner With Lyft, Uber? Analyst Has &#8216;Rising Conviction&#8217; For Future Partnership</a>
<h3 class="wp-block-heading">What The Data Says</h3>
The numbers don't lie: as yields climb, stock allocations typically fall. BofA's proprietary sell-side indicator shows that when 10-year yields rise above 5%, Wall Street tends to trim stock allocations. 
When yields hit 6% or high, the average investor portfolio's equity allocation shrinks to around 50%.
David Rosenberg, a veteran economist, echoed this sentiment on social media platform X, writing earlier this week, "With this move in bond yields, we are now just 10 basis points away from the Equity Risk Premium shifting negative. Ergo, investors are willing to pay to take on equity risk instead of getting paid to."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">With this move in bond yields, we are now just 10 basis points away from the Equity Risk Premium shifting negative. Ergo, investors are willing to pay to take on equity risk instead of getting paid to. <a href="https://t.co/U7uzIOOuU1">pic.twitter.com/U7uzIOOuU1</a>
&mdash; David Rosenberg (@EconguyRosie) <a href="https://twitter.com/EconguyRosie/status/1856399690058870839?ref_src=twsrc%5Etfw">November 12, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h3 class="wp-block-heading">But Wait—Stocks Don't Always Follow the Rules</h3>
Before you start dumping your Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares for Treasuries, it's worth noting that the equity risk premium isn't perfect at predicting short-term market moves. 
In fact, periods of low or even negative ERP can persist for months or years while stocks continue to perform well.
For example, in 2023 and 2024, the S&amp;P 500 operated under a low or zero ERP but still delivered stellar returns, defying expectations. 
Bank of America acknowledged this potential for resilience. Real rates today—defined as the difference between the yield of a Treasury at 10 years and the 10-year inflation expectations—are around 2%, &#8220;but they can move higher without impacting equities."
In prior cycles, like the productivity boom from 1985 to 2005, real rates averaged 3.5%, yet the S&amp;P 500 posted annual returns of 15%.
<h3 class="wp-block-heading">A Manageable Rate Risk For S&amp;P 500 Companies?</h3>
Despite rising yields, the S&amp;P 500 may be more insulated than some investors think. 
Around 80% of S&amp;P 500 debt is long-term and fixed, compared to less than 50% in 2008. This means companies are less exposed to the immediate impact of higher bond yields.
Additionally, the current real yield of roughly 2% is consistent with historical averages since 1950. While rates could climb further, it doesn't necessarily spell doom for equities.
Bottom line, if 10-year Treasury yields climb above 5%, it could fundamentally shift the risk-reward equation for stocks versus bonds, luring investors toward safer assets. But, the validity of the equity risk premium for market timing is not a crystal ball. 
Historical trends and current market conditions suggest stocks may still find a way to thrive, even in a higher-rate environment.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42013424/trumps-musk-ramaswamy-doge-plan-what-it-means-for-defense-and-it-stocks">Trump&#8217;s DOGE Plan: Goldman Sachs Says Defense Stocks Face Risks, IT Firms Could Win</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Bonds

Treasuries

Economics

NVDA

Return To 5% Bond Yields Could Tempt Investors: Are Stocks At Risk Of Losing Out?

Martha Stewart, the queen of home and garden and <a href="https://www.benzinga.com/news/24/08/40115264/martha-stewart-is-pissed-at-elon-musk-says-cybertruck-is-too-crazy-for-her-i-loved-tesla">America&#8217;s original influencer</a>, recently shared a surprising tidbit about one of her closest collaborators: Snoop Dogg. The famous rapper, known for his cool style and relaxed personality, has been a surprising but helpful mentor to Stewart when it comes to learning how to negotiate.
Don't Miss:
<ul>
<li>The global games market is projected to generate $272B by the end of the year –<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
</ul>
Martha discussed the lessons she gained from Snoop in a recent interview with The Wall Street Journal, stating, &#8220;I&#8217;ve learned how to negotiate even better than ever.&#8221; The two have collaborated on several projects, such as <a href="https://www.benzinga.com/general/24/04/38111169/snoop-dogg-and-martha-stewart-are-making-millions-as-unlikely-powerhouse-duo-collab-on-everything-fr">their popular culinary show</a>, &#8220;Martha &amp; Snoop&#8217;s Potluck Dinner Party,&#8221; where their peculiar bond developed. Martha explained that when they work together, she watches how Snoop handles contract negotiations and she has picked up some savvy techniques by following his lead.
&#8220;We do a lot of work together and I wait for him to negotiate the contract, then I go and follow him,&#8221; she added with a laugh. Snoop's approach, often described as confident but easygoing, has left an impression on Stewart, who says she's applying some of his methods to her business dealings.
Trending: With over 7.8K investors including Meta, Google, and Amazon Execs – this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today before the offer closes in 2 weeks.</a>
It&#8217;s a bit of a role reversal – you&#8217;d expect Martha to be teaching the lessons, especially in a business setting. After all, her rise to success is nothing short of iconic. She was a model and then a stockbroker in New York City before becoming the Martha Stewart we know today.&nbsp;
She quit Wall Street in the 1970s to launch her own catering business out of her kitchen, which would eventually result in the development of her enormous media empire. Her first book, published in 1982 and simply called "Entertaining," became an instant hit and established her as the go-to expert for cooking and lifestyle advice.
By the 1990s, Martha had launched her magazine, Martha Stewart Living and in 1999, she became America&#8217;s first self-made female billionaire when her company, Martha Stewart Living Omnimedia, went public. Although serving time in prison for conspiracy and making false statements in 2004 dealt a serious blow to her career, Martha bounced back stronger than ever, using her trademark flair and tenacity to launch new projects and grow her brand.
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing –<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
Even with all of this under her belt – building a business empire, authoring nearly 100 books and staging a remarkable comeback after a public fall – Martha still sees value in learning from others. This is where Snoop comes in.
The two have become quite the dynamic duo since they first connected in 2008, when Martha invited Snoop onto her daytime talk show to make mashed potatoes. Unquestionably, they clicked and ever since, they have remained friends and <a href="https://www.benzinga.com/general/24/04/38111169/snoop-dogg-and-martha-stewart-are-making-millions-as-unlikely-powerhouse-duo-collab-on-everything-fr">worked together on several great projects</a>, including Comedy Central&#8217;s roast of Justin Bieber.
Despite having completely different personalities, they seem to complement one another well, whether they&#8217;re tackling difficult business situations or cooking up a storm. Stewart&#8217;s readiness to pick up tips from Snoop demonstrates that even the most seasoned businesspeople can benefit from fresh perspectives. It also shows that sometimes the most unexpected people teach the best lessons.
Read Next:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before closing date.</a></li>
</ul>

Startups

Martha Stewart Reveals An Unexpected Mentor Who Helped Her 'Negotiate Even Better Than Ever'

Editor&#8217;s note: This story has been updated with comment from Fox News. 
Economist and news analyst Larry Kudlow could return to a role in the White House with the former National Economic Council Director being eyed for a role among Donald Trump's growing list of possible <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">Cabinet nominees and advisors.</a>
What Happened: Kudlow, who is a Fox Business Network host, served as the<a href="https://www.benzinga.com/topic/larry-kudlow"> National Economic Council Director </a>for Trump from 2018 to 2021.
Kudlow is being eyed to return to the Trump administration after Trump's recent win in the<a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election"> 2024 presidential election.</a>
The economist, who met with Trump recently at Mar-a-Lago, could be considered to lead the National Economic Council once again or for a role within the Treasury Department, as <a href="https://www.wsj.com/politics/larry-kudlow-economic-role-trump-cabinet-3af2a446?mod=hp_lead_pos2">reported </a>Friday by the Wall Street Journal.
Kudlow has remained in touch with Trump since leaving the White House and has spoken positively of the president-elect on Fox Business, leading to Trump allies supporting the economist&#8217;s return to a White House role, according to the report.
Fox News told Benzinga in a statement Friday that Kudlow isn&#8217;t going anywhere. 
"Larry Kudlow recently signed a new deal to continue hosting his eponymous program on FOX Business and has no plans to leave his current role helming one of the highest rated shows on the network,&#8221; a Fox spokesperson said. 
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent111524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Kudlow began his role as National Economic Council Director in April 2018 and remained in the role until the end of Trump's presidency. While other members of Trump's cabinet and administration left or got fired, Kudlow stayed. 
Reports of Kudlow being considered for a White House role comes as some Trump allies say there is a growing battle between several candidates like Howard Lutnick and Scott Bessent for economic roles in the Trump administration.
The campaigning for the role of Treasury secretary has upset Trump, according to the report, which could mean he goes a different direction in naming his new economic advisor and leadership picks.
Other names being considered for economic positions include Apollo Global Management CEO Marc Rowan and former U.S. trade representative Robert Lighthizer, the WSJ reported. 
The week has been full of several announcements from Trump on who he is planning to nominate for key White House roles once his term begins in January. More announcements are expected between now and then. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/11/41956594/matt-gaetz-is-trumps-attorney-general-pick-would-be-top-cop-is-under-house-ethics-investigation">Matt Gaetz Is Trump&#8217;s Attorney General Pick: Would-Be Top Cop Is Under House Ethics Investigation</a></li>
</ul>
Photo via Shutterstock.

Government

Politics

Larry Kudlow As Trump Economic Advisor? Fox Business Host Under Consideration For Return To White House (UPDATED)

Barrington Research analyst Alexander Paris maintains Universal Technical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>) with a Outperform and maintains $22 price target.

Barrington Research Maintains Outperform on Universal Technical, Maintains $22 Price Target

BWS Financial analyst Hamed Khorsand maintains Sable Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) with a Sell and maintains $6 price target.

BWS Financial Maintains Sell on Sable Offshore, Maintains $6 Price Target

AdvisorShares, a pioneer in the cannabis investing space, offering global, domestic, and leveraged actively managed cannabis ETFs, has announced a reverse split of the issued and outstanding shares of the AdvisorShares MSOS Daily Leveraged ETF. The split will not change the total value of a shareholder's investment.
MSOX&nbsp; has a daily leveraged investment objective and is designed for experienced and sophisticated active day trading investors only. While the investment object is still designed to target two times the exposure the Fund will typically be in range above or below the two times leverage target. This ETF was built to provide more liquidity to these companies in this growing industry, but it's important for investors to remember this ETF is designed only for experienced and sophisticated active day trading investors. Please read the MSOX prospectus for all the risks associated with this ETF.
Effective before market open on November 26, 2024, the Fund will affect a reverse split of its issued and outstanding shares as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Fund Name</td>
<td colspan="1" rowspan="1">Reverse Split Ratio</td>
<td colspan="1" rowspan="1">Approximate decrease in total number of outstanding shares</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">AdvisorShares MSOS Daily Leveraged ETF</td>
<td colspan="1" rowspan="1">1 for 20</td>
<td colspan="1" rowspan="1">95&nbsp;%</td>
</tr>
</tbody>
</table>
</figure>
Please note the CUSIP changes, effective November 26, 2024:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Fund Name</td>
<td colspan="1" rowspan="1">Ticker</td>
<td colspan="1" rowspan="1">Current CUSIP</td>
<td colspan="1" rowspan="1">New CUSIP</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">AdvisorShares MSOS Daily Leveraged ETF</td>
<td colspan="1" rowspan="1">MSOX</td>
<td colspan="1" rowspan="1">00768Y313</td>
<td colspan="1" rowspan="1">00768Y289</td>
</tr>
</tbody>
</table>
</figure>
As a result of this reverse split, every twenty shares of the Fund will be exchanged for one share as indicated above. Accordingly, the total number of the issued and outstanding shares for the Fund will decrease by the approximate percentage indicated above. In addition, the per share net asset value (NAV) and next day's opening market price will be approximately twenty times higher for the Fund. Shares of the Fund will begin trading on the NYSE Arca on a split-adjusted basis on November 26, 2024.
A shareholder's investment value will not be affected by the reverse split. The table below illustrates the effect of a hypothetical one-for-twenty reverse split anticipated for the Fund, as applicable and described above:
&nbsp;1-for-20 Reverse Split
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Period</td>
<td colspan="1" rowspan="1"># of Shares Owned&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td colspan="1" rowspan="1">Hypothetical NAV &nbsp; &nbsp;&nbsp;</td>
<td colspan="1" rowspan="1">Total Market Value</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Pre-Split</td>
<td colspan="1" rowspan="1">1,000</td>
<td colspan="1" rowspan="1">$10</td>
<td colspan="1" rowspan="1">$10,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Post-Split &nbsp; &nbsp;&nbsp;</td>
<td colspan="1" rowspan="1">50</td>
<td colspan="1" rowspan="1">$200</td>
<td colspan="1" rowspan="1">$10,000</td>
</tr>
</tbody>
</table>
</figure>
The Trust's transfer agent will notify the Depository Trust Company (DTC) of the reverse split and instruct DTC to adjust each shareholder's investment(s) accordingly. DTC is the registered owner of the Fund's shares and maintains a record of the Fund's record owners.
Redemption of Fractional Shares and Tax Consequences for the Reverse Split
As a result of the reverse split, a shareholder of the Fund's shares potentially could hold a fractional share. However, fractional shares cannot trade on the NYSE Arca. Thus, the Fund will redeem for cash a shareholder's fractional shares at the Fund's split-adjusted NAV as of the Effective Date. A shareholder could recognize a gain or loss in connection with the redemption of the shareholder's fractional shares.
"Odd Lot" Unit
As a result of the reverse split, the Fund may have outstanding one aggregation of less than 5,000 shares to make a creation unit, or an "odd lot unit." Thus, the Fund will provide one authorized participant with a one-time opportunity to redeem the odd lot unit after the split-adjusted NAV is struck on November 26, 2024.

AdvisorShares Trust AdvisorShares MSOS 2x Daily ETF

MSOX

AdvisorShares Announces 1-For-20 Reverse Split Of ETF

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report...

Edgewise Therapeutics (EWTX) Gets a Buy from Truist Financial

Capricor stock rallies 20% on DMD data presentation update

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vertex Pharmaceuticals (VRTX – Research Report), A...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX), AnaptysBio (ANAB) and Edgewise Therapeutics (EWTX)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Edgewise Therapeutics (EWTX – Research Report) and A...

Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX) and AnaptysBio (ANAB)

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today and set a price target of $51....

Piper Sandler Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX)

Capricor reports positive long-term data for DMD drug deramiocel

Truist Financial analyst Srikripa Devarakonda assigned a Buy rating to the stock today. The company's shares closed yesterday at $34.85. Devarakond...

Truist Financial Gives a Buy Rating to Edgewise Therapeutics (EWTX)

Edgewise Therapeutics reports Q3 results

Edgewise Therapeutics, Inc. ( ($EWTX) ) has released its Q3 earnings. Here is a breakdown of the information Edgewise Therapeutics, Inc. presented ...

Edgewise Therapeutics Reports Q3 Progress in Muscle Disease Trials

RBC Capital analyst Leonid Timashev assigned a Buy rating to Edgewise Therapeutics (EWTX – Research Report) yesterday and set a price target of $42...

RBC Capital Releases a Buy Rating on Edgewise Therapeutics (EWTX)

ANAB

CAPR

CPRX

MSCLF

RGNX

RHHBY

SLDB

SRPT

TRDA

VRTX

Press Releases

Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies

Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)

Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024

Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Edgewise Therapeutics

매도 수량

Edgewise Therapeutics (NASDAQ:EWTX) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌